Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025
Organogenesis Holdings (Nasdaq: ORGO), a regenerative medicine company specializing in Advanced Wound Care and Surgical and Sports Medicine markets, has announced it will release its fourth quarter and fiscal year 2024 financial results after market close on February 27th, 2025.
Management will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss quarterly and annual results, provide a corporate update, and conduct a Q&A session. The event will be accessible via live webcast through the company's investor relations website, where it will remain archived for approximately one year.
Organogenesis Holdings (Nasdaq: ORGO), un'azienda di medicina rigenerativa specializzata nei mercati della Cura Avanzata delle Ferite e della Medicina Chirurgica e Sportiva, ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'anno fiscale 2024 dopo la chiusura del mercato il 27 febbraio 2025.
La direzione ospiterà una conferenza telefonica alle 17:00 ora orientale dello stesso giorno per discutere i risultati trimestrali e annuali, fornire un aggiornamento aziendale e condurre una sessione di domande e risposte. L'evento sarà accessibile tramite webcast dal vivo attraverso il sito web delle relazioni con gli investitori dell'azienda, dove rimarrà archiviato per circa un anno.
Organogenesis Holdings (Nasdaq: ORGO), una compañía de medicina regenerativa especializada en los mercados de Cuidado Avanzado de Heridas y Medicina Quirúrgica y Deportiva, ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año fiscal 2024 después del cierre del mercado el 27 de febrero de 2025.
La dirección llevará a cabo una conferencia telefónica a las 5:00 p.m. hora del Este el mismo día para discutir los resultados trimestrales y anuales, proporcionar una actualización corporativa y realizar una sesión de preguntas y respuestas. El evento será accesible a través de un webcast en vivo a través del sitio web de relaciones con inversores de la compañía, donde permanecerá archivado durante aproximadamente un año.
Organogenesis Holdings (Nasdaq: ORGO), 고급 상처 치료 및 외과 및 스포츠 의학 시장을 전문으로 하는 재생 의학 회사는 2024 회계연도 4분기 재무 결과를 2025년 2월 27일 시장 종료 후 발표할 것이라고 발표했습니다.
경영진은 동일한 날 오후 5시(동부 표준시)에 분기 및 연간 결과를 논의하고, 기업 업데이트를 제공하며, Q&A 세션을 진행하기 위한 컨퍼런스 콜을 개최합니다. 이 이벤트는 회사의 투자자 관계 웹사이트를 통해 라이브 웹캐스트로 접근할 수 있으며, 약 1년 동안 아카이브로 남게 됩니다.
Organogenesis Holdings (Nasdaq: ORGO), une entreprise de médecine régénérative spécialisée dans les marchés des soins avancés des plaies et de la médecine chirurgicale et sportive, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'exercice 2024 après la fermeture du marché le 27 février 2025.
La direction animera une conférence téléphonique à 17h00, heure de l'Est, le même jour pour discuter des résultats trimestriels et annuels, fournir une mise à jour de l'entreprise et réaliser une session de questions-réponses. L'événement sera accessible via un webinaire en direct sur le site web des relations investisseurs de l'entreprise, où il restera archivé pendant environ un an.
Organogenesis Holdings (Nasdaq: ORGO), ein Unternehmen für regenerative Medizin, das sich auf die Märkte der fortschrittlichen Wundversorgung sowie der chirurgischen und Sportmedizin spezialisiert hat, hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal und das Geschäftsjahr 2024 nach Börsenschluss am 27. Februar 2025 veröffentlichen wird.
Das Management wird am selben Tag um 17:00 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Quartals- und Jahresergebnisse zu besprechen, ein Unternehmensupdate zu geben und eine Q&A-Sitzung durchzuführen. Die Veranstaltung wird über einen Live-Webcast über die Investor-Relations-Website des Unternehmens zugänglich sein, wo sie etwa ein Jahr lang archiviert bleibt.
- None.
- None.
CANTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2024 financial results will be reported after the market closes on Thursday, February 27th.
Management will host a conference call at 5:00 p.m. Eastern Time on February 27th to discuss the results of the quarter and fiscal year, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.
FAQ
When will Organogenesis (ORGO) report Q4 2024 earnings?
How can investors access ORGO's Q4 2024 earnings call?
How long will ORGO's Q4 2024 earnings webcast be available?
What time is Organogenesis (ORGO) Q4 2024 earnings call?
